All Relations between Alzheimer Disease and cannabinoids

Publication Sentence Publish Date Extraction Date Species
Jiang Wu, Bihua Bie, Hui Yang, Jijun J Xu, David L Brown, Mohamed Nagui. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiology of aging. vol 34. issue 3. 2013-05-24. PMID:22795792. cannabinoid type 2 (cb(2)) agonists are neuroprotective and appear to play modulatory roles in neurodegenerative processes in alzheimer's disease. 2013-05-24 2023-08-12 rat
Marek Tkaczyk, Ewa Florek, Wojciech Piekoszewsk. [Marihuana and cannobinoids as medicaments]. Przeglad lekarski. vol 69. issue 10. 2013-04-10. PMID:23421098. another studies indicates that cannabinoids play role in treatment of neurological disorders like alzheimer disease or amyotrophic lateral sclerosis (als) or even can reduce spreading of tumor cells. 2013-04-10 2023-08-12 Not clear
Cristina Benito, Rosa María Tolón, Ana Isabel Castillo, Lourdes Ruiz-Valdepeñas, José Antonio Martínez-Orgado, Francisco Javier Fernández-Sánchez, Carmen Vázquez, Benjamin F Cravatt, Julián Romer. β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors. British journal of pharmacology. vol 166. issue 4. 2012-10-09. PMID:22321194. the endocannabinoid system may regulate glial cell functions and their responses to pathological stimuli, specifically, alzheimer's disease. 2012-10-09 2023-08-12 Not clear
Tim Karl, David Cheng, Brett Garner, Jonathon C Arnol. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert opinion on therapeutic targets. vol 16. issue 4. 2012-08-07. PMID:22448595. the therapeutic potential of the endocannabinoid system for alzheimer's disease. 2012-08-07 2023-08-12 Not clear
Benjamin S Harvey, Katharina S Ohlsson, Jesper L V Mååg, Ian F Musgrave, Scott D Smi. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology. vol 33. issue 1. 2012-06-04. PMID:22233683. in this study we compared the effects of cb1 and cb2 receptor-selective ligands, the endocannabinoid anandamide and the phytocannabinoid cannabidiol, against oxidative stress and the toxic hallmark alzheimer's protein, β-amyloid (aβ) in neuronal cell lines. 2012-06-04 2023-08-12 Not clear
Jasinda H Lee, Grzegorz Agacinski, Jonathan H Williams, Gordon K Wilcock, Margaret M Esiri, Paul T Francis, Peter T-H Wong, Christopher P Chen, Mitchell K P La. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochemistry international. vol 57. issue 8. 2011-11-22. PMID:21034788. intact cannabinoid cb1 receptors in the alzheimer's disease cortex. 2011-11-22 2023-08-12 human
Jasinda H Lee, Grzegorz Agacinski, Jonathan H Williams, Gordon K Wilcock, Margaret M Esiri, Paul T Francis, Peter T-H Wong, Christopher P Chen, Mitchell K P La. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochemistry international. vol 57. issue 8. 2011-11-22. PMID:21034788. the cannabinoid cb1 receptor has gained much attention as a potential pharmacotherapeutic target in various neurodegenerative diseases including alzheimer's disease (ad). 2011-11-22 2023-08-12 human
Ana María Martín-Moreno, David Reigada, Belén G Ramírez, R Mechoulam, Nadia Innamorato, Antonio Cuadrado, María L de Ceballo. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Molecular pharmacology. vol 79. issue 6. 2011-08-01. PMID:21350020. cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to alzheimer's disease. 2011-08-01 2023-08-12 mouse
Jan Mulder, Misha Zilberter, Susana J Pasquaré, Alán Alpár, Gunnar Schulte, Samira G Ferreira, Attila Köfalvi, Ana M Martín-Moreno, Erik Keimpema, Heikki Tanila, Masahiko Watanabe, Ken Mackie, Tibor Hortobágyi, Maria L de Ceballos, Tibor Harkan. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain : a journal of neurology. vol 134. issue Pt 4. 2011-07-01. PMID:21459826. comparative protein profiling and quantitative morphometry showed that overall cb(1) cannabinoid receptor protein levels in the hippocampi of patients with alzheimer's disease remain unchanged relative to age-matched controls, and cb(1) cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. 2011-07-01 2023-08-12 mouse
Jan Mulder, Misha Zilberter, Susana J Pasquaré, Alán Alpár, Gunnar Schulte, Samira G Ferreira, Attila Köfalvi, Ana M Martín-Moreno, Erik Keimpema, Heikki Tanila, Masahiko Watanabe, Ken Mackie, Tibor Hortobágyi, Maria L de Ceballos, Tibor Harkan. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain : a journal of neurology. vol 134. issue Pt 4. 2011-07-01. PMID:21459826. hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite alzheimer's (braak stage vi), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing cb(1) cannabinoid receptor-positive presynapses. 2011-07-01 2023-08-12 mouse
Alexandra Kibbl. American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2. IDrugs : the investigational drugs journal. vol 13. issue 10. 2011-03-29. PMID:20878583. this conference report highlights selected presentations on (s)-adenosylhomocysteine (ahcy) inhibitors for the treatment of alzheimer's disease, 2,4-diphenyl-1h-imidazole analogs as cannabinoid cb2 agonists for the treatment of pain, checkpoint kinase 1 (chk1) and aurora kinase b as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as vegfr2 inhibitors, and janus kinase 2 (jak2) for the treatment of myeloproliferative disorders. 2011-03-29 2023-08-12 Not clear
B Chen, K Bromley-Brits, G He, F Cai, X Zhang, W Son. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Current Alzheimer research. vol 7. issue 3. 2010-08-12. PMID:20043809. effect of synthetic cannabinoid hu210 on memory deficits and neuropathology in alzheimer's disease mouse model. 2010-08-12 2023-08-12 mouse
B Chen, K Bromley-Brits, G He, F Cai, X Zhang, W Son. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Current Alzheimer research. vol 7. issue 3. 2010-08-12. PMID:20043809. here we investigate whether cannabinoids have any effect on alzheimer's disease in vivo. 2010-08-12 2023-08-12 mouse
Christopher J Fowler, Maria Luisa Rojo, Antonio Rodriguez-Gaztelumend. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20353772. in terms of the clinical usefulness of targeting the endocannabinoid system for the treatment of neurodegenerative disorders, data are emerging, but important factors to be considered are windows of opportunity (for acute situations such as trauma and ischemia) and the functionality of the target receptors (for chronic neurodegenerative disorders such as alzheimer's disease). 2010-06-28 2023-08-12 Not clear
J Romero, J Martínez Orgad. Cannabinoids and neurodegenerative diseases. CNS & neurological disorders drug targets. vol 8. issue 6. 2010-02-12. PMID:19839933. the present review will focus on the existing data regarding the possible usefulness of cannabinoid agents for the treatment of relevant neurological pathologies for our society such as alzheimer's disease, multiple sclerosis, huntington's disease and amyotrophic lateral sclerosis. 2010-02-12 2023-08-12 Not clear
Rosa María Tolón, Estefanía Núñez, María Ruth Pazos, Cristina Benito, Ana Isabel Castillo, José Antonio Martínez-Orgado, Julián Romer. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain research. vol 1283. 2009-10-23. PMID:19505450. these data corroborate the possible therapeutic interest of cb(2) cannabinoid specific chemicals in the treatment of alzheimer's disease. 2009-10-23 2023-08-12 human
José Martínez Orgado, Javier Fernández-Ruiz, Julián Romer. The endocannabinoid system in neuropathological states. International review of psychiatry (Abingdon, England). vol 21. issue 2. 2009-08-04. PMID:19367511. among the group of brain disorders that have been associated with the endocannabinoid system, a special interest has been concentrated in various neurodegenerative diseases, including alzheimer's disease, parkinson's disease and ischemia. 2009-08-04 2023-08-12 Not clear
Sarada Krishnan, Ruth Cairns, Robert Howar. Cannabinoids for the treatment of dementia. The Cochrane database of systematic reviews. issue 2. 2009-06-23. PMID:19370677. recent studies have also shown that cannabinoids may have more specific effects in interrupting the pathological process in alzheimer's disease. 2009-06-23 2023-08-12 Not clear
Jeremy Koppel, Heather Bradshaw, Terry E Goldberg, Houman Khalili, Philippe Marambaud, Michael J Walker, Miguel Pazos, Marc L Gordon, Erica Christen, Peter Davie. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids in health and disease. vol 8. 2009-02-27. PMID:19144193. neuropathological, animal, and cell culture studies point to a role for the body's own endogenous cannabinoids (ecbs) system in alzheimer's disease (ad) pathology and treatment. 2009-02-27 2023-08-12 Not clear
Yannick Marchalant, Francesca Cerbai, Holly M Brothers, Gary L Wen. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiology of aging. vol 29. issue 12. 2009-01-23. PMID:17561311. stimulation of cannabinoid receptors may provide clinical benefits in age-related diseases that are associated with brain inflammation, such as alzheimer's disease. 2009-01-23 2023-08-12 rat